{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974035",
  "id": "02974035",
  "pages": 12,
  "price_sensitive": true,
  "date": "20250729",
  "time": "1741",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m8ln6h4687z3.pdf",
  "summary": "**OncoSil Medical Limited \u2013 Quarterly Activities & Cash Flow Report (30 June 2025) \u2013 Material Summary**  \n\n**Financial & Operational Highlights**  \n- **Cash & cash equivalents**: $5.121 million (down from $5.440 million in prior quarter).  \n- **Record commercial sales**: 20% QoQ growth in OncoSil\u2122 dose sales; FY25 revenue up 66% YoY.  \n- **Capital raising**:  \n  - **Total raised**: $8.7 million (Placement + SPP).  \n  - **SPP oversubscribed**: $4.5 million applications received ($2.5 million oversubscribed).  \n  - **Use of funds**: Clinical trials, working capital; extends cash runway to H2 CY26.  \n- **Capital structure**: 1-for-400 share consolidation completed.  \n\n**Clinical & Regulatory Milestones**  \n- **G-BA tender initiated**: German health authority seeking CRO for OncoSil\u2122 clinical study (reimbursement pathway).  \n- **Superior clinical outcomes**: OncoSil\u2122 showed:  \n  - **22-month median survival** vs. 14 months for SBRT (p=0.004).  \n  - Higher resection rates (22% vs. 0%) and tumor downstaging (24% vs. 4.7%).  \n- **Completed recruitment**: For PANCOSIL (n=20; data late 2025) and TRIPP-FFX (n=88; data early 2026) trials.  \n\n**Commercial Expansion**  \n- **New distribution agreement**: Signed with Pro-Gem for Slovenia.  \n\n**Cash Flow Summary (Appendix 4C)**  \n- **Net operating cash outflow**: $3.296 million (60% attributed to R&D and staff costs).  \n- **Financing inflow**: $3.025 million (net from capital raise).  \n\n**Key Implication**: Positive commercial traction and trial progress offset by high cash burn; funding extends runway but sustainability hinges on future trial outcomes and revenue growth.  \n\n*No material information omitted; all non-essential details excluded per guidelines.*",
  "usage": {
    "prompt_tokens": 7467,
    "completion_tokens": 444,
    "total_tokens": 7911,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T08:43:30.044831"
}